Format

Send to

Choose Destination
Can J Cardiol. 2019 Mar;35(3):288-298. doi: 10.1016/j.cjca.2019.01.005.

Pulmonary Hypertension in HIV.

Author information

1
MedStar Heart and Vascular Institute, Washington Hospital Center, Washington, DC, USA.
2
MedStar Heart and Vascular Institute, Washington Hospital Center, Washington, DC, USA; MedStar Georgetown University Hospital, Washington, DC, USA.
3
MedStar Heart and Vascular Institute, Washington Hospital Center, Washington, DC, USA; MedStar Georgetown University Hospital, Washington, DC, USA. Electronic address: Christopher.Barnett@Medstar.net.

Abstract

Human immunodeficiency virus-associated pulmonary arterial hypertension (HIV-PAH) is important to recognize given its association with significant morbidity and mortality. With the introduction of antiretroviral therapy, the focus of disease management has largely shifted from treating immunodeficiency-related opportunistic infections to managing chronic cardiopulmonary complications. Symptoms are nonspecific, and a high index of clinical suspicion is needed to avoid significant delay in the diagnosis of HIV-PAH. Although several viral proteins have been implicated in the pathogenesis of HIV-PAH, the exact mechanism remains uncertain. Further studies are needed to elucidate precise pathogenic mechanisms, early diagnostic tools, and novel therapeutic targets to improve prognosis of this severe complication.

PMID:
30825951
DOI:
10.1016/j.cjca.2019.01.005

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center